- Home
- ANAB vs NAT Comparison
ANAB vs NAT Comparison
Compare ANAB & NAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANAB | NAT |
|---|---|---|
| Founded | 2005 | 1995 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2015 | 1997 |
Fundamental Metrics
Financial Performance| Metric | ANAB | NAT |
|---|---|---|
| Price | $62.39 | $5.88 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 12 | 2 |
| Target Price | ★ $71.67 | $4.00 |
| AVG Volume (30 Days) | 570.6K | ★ 5.4M |
| Earning Date | 05-08-2026 | 05-28-2026 |
| Dividend Yield | N/A | ★ 8.50% |
| EPS Growth | ★ 91.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $234,603,000.00 | N/A |
| Revenue This Year | N/A | $77.72 |
| Revenue Next Year | $52.14 | N/A |
| P/E Ratio | ★ N/A | $525.49 |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $17.11 | $2.63 |
| 52 Week High | $73.30 | $6.70 |
Technical Indicators
Market Signals| Indicator | ANAB | NAT |
|---|---|---|
| Relative Strength Index (RSI) | 56.57 | 53.99 |
| Support Level | $52.32 | $5.07 |
| Resistance Level | $67.69 | $6.30 |
| Average True Range (ATR) | 3.27 | 0.33 |
| MACD | 0.87 | -0.01 |
| Stochastic Oscillator | 54.78 | 41.11 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About NAT Nordic American Tankers Limited
Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.